Fumihiro Fujiki

2.3k citations

42 papers · 580 indexed · h-index 15

Immunology top 10%
- Immunotherapy and Immune Responses 20
- Immune Cell Function and Interaction 5
- T-cell and B-cell Immunology 4
Oncology top 10%
- CAR-T cell therapy research 22
- Cancer Immunotherapy and Biomarkers 5
Molecular Biology
- Renal and related cancers 24
- Epigenetics and DNA Methylation 5
- RNA Interference and Gene Delivery 3
Hematology
Genetics

Co-authors: Haruo Sugiyama Akihiro Tsuboi Hiroko Nakajima Yusuke Oji Yoshitaka Oka Naoki Hosen Sumiyuki Nishida Soyoko Morimoto
Cited by: Immunology Oncology Molecular Biology
Journals: Blood (1 paper)PLoS ONE (4 papers)Neurology (1 paper)
Partner nations: Japan Australia United States

In The Last Decade

Fumihiro Fujiki

41 papers receiving 574 citations

Peers

Countries citing papers authored by Fumihiro Fujiki

Since Specialization

Citations

This map shows the geographic impact of Fumihiro Fujiki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fumihiro Fujiki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fumihiro Fujiki more than expected).

Fields of papers citing papers by Fumihiro Fujiki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fumihiro Fujiki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fumihiro Fujiki. The network helps show where Fumihiro Fujiki may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Fumihiro Fujiki, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Fumihiro Fujiki Line = papers co-authored together Fumihiro Fujiki links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	LBA4: Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable (UR) stage III EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC): Updated overall survival (OS) analysis from the LAURA study Journal of Thoracic Oncology ·Sundar Ramalingam,Mustafa Özgüroğlu,M-J. Ahn,Xiaorong Dong,J.C-H. Yang,S. Oizumi,Keisuke Goto,M.A. Cobo Dols,S-W. Kim,T-C. Hsia,Jarin Chindaprasirt,Fumihiro Fujiki,Niki Lama,Ignacio Casarini,T. Kato,X. Huang,Annette Evans,Ana Bolanos,Shun Lü	2025	3
2	Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia BMC Cancer ·Hikaru Minagawa,Yoshiko Hashii,Hiroko Nakajima,Fumihiro Fujiki,Soyoko Morimoto,Jun Nakata,Toshiro Shirakawa,Takane Katayama,Akihiro Tsuboi,Keiichi Ozono	2023	5
3	Establishment of a novel NFAT-GFP reporter platform useful for the functional avidity maturation of HLA class II-restricted TCRs Cancer Immunology Immunotherapy ·Fumihiro Fujiki,Soyoko Morimoto,Yuya Nishida,Satoe Tanii,Nao Aoyama,Miki Inatome,Kento Inoue,Akiko Katsuhara,Hiroko Nakajima,Jun Nakata,Sumiyuki Nishida,Akihiro Tsuboi,Yoshitaka Oka,Yusuke Oji,Shinji Sogo,Haruo Sugiyama	2023	1
4	An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia Cancer Immunology Immunotherapy ·Natsuki Nakagawa,Yoshiko Hashii,Hisako Kayama,Ryu Okumura,Hiroko Nakajima,Hikaru Minagawa,Soyoko Morimoto,Fumihiro Fujiki,Jun Nakata,Toshiro Shirakawa,Takane Katayama,Kiyoshi Takeda,Akihiro Tsuboi,Keiichi Ozono	2022	14
5	T Cell-Intrinsic Vitamin A Metabolism and Its Signaling Are Targets for Memory T Cell-Based Cancer Immunotherapy Frontiers in Immunology ·Fumihiro Fujiki,Soyoko Morimoto,Akiko Katsuhara,Akane Okuda,Saeka Ogawa,Eriko Ueda,Maki Miyazaki,Ayako Isotani,Masahito Ikawa,Sumiyuki Nishida,Hiroko Nakajima,Akihiro Tsuboi,Yoshitaka Oka,Jun Nakata,Naoki Hosen,Atsushi Kumanogoh,Yusuke Oji,Haruo Sugiyama	2022	8
6	Imaging Assessment of Tumor Response in the Era of Immunotherapy Diagnostics ·Jun Nakata,Kayako Isohashi,Yoshitaka Oka,Hiroko Nakajima,Soyoko Morimoto,Fumihiro Fujiki,Yusuke Oji,Akihiro Tsuboi,Atsushi Kumanogoh,Naoya Hashimoto,Jun Hatazawa,Haruo Sugiyama	2021	7
7	Identification of mouse helper epitopes for WT1-specific CD4+ T cells Cancer Immunology Immunotherapy ·Hiroko Nakajima,Jun Nakata,Kanako Imafuku,Hiromu Hayashibara,Kazuki Isokawa,Keiko Udaka,Fumihiro Fujiki,Soyoko Morimoto,Kana Hasegawa,Naoki Hosen,Yoshiko Hashii,Sumiyuki Nishida,Akihiro Tsuboi,Yoshitaka Oka,Yusuke Oji,Shinji Sogo,Haruo Sugiyama	2021	6
8	Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides Cancer Immunology Immunotherapy ·Fumihiro Fujiki,Akihiro Tsuboi,Soyoko Morimoto,Naoya Hashimoto,Miki Inatome,Hiroko Nakajima,Jun Nakata,Sumiyuki Nishida,Kana Hasegawa,Naoki Hosen,Yoshitaka Oka,Yusuke Oji,Shinji Sogo,Haruo Sugiyama	2020	7
9	Regeneration of Tumor-Antigen-Specific Cytotoxic T Lymphocytes from iPSCs Transduced with Exogenous TCR Genes Molecular Therapy — Methods & Clinical Development ·Takuya Maeda,Seiji Nagano,Soki Kashima,Koji Terada,Yasutoshi Agata,Hiroshi Ichise,Manami Ohtaka,Mahito Nakanishi,Fumihiro Fujiki,Haruo Sugiyama,Toshio Heike,Norimitsu Kadowaki,Akifumi Takaori‐Kondo,Kyoko Masuda,Hiroshi Kawamoto	2020	14
10	A phase I clinical study of a cocktail vaccine of Wilms’ tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma Cancer Immunology Immunotherapy ·Akihiro Tsuboi,Naoya Hashimoto,Fumihiro Fujiki,Soyoko Morimoto,Naoki Kagawa,Hiroko Nakajima,Naoki Hosen,Sumiyuki Nishida,Jun Nakata,Satoshi Morita,Junichi Sakamoto,Yusuke Oji,Yoshitaka Oka,Haruo Sugiyama	2018	43
11	An Essential Role of the Avidity of T-Cell Receptor in Differentiation of Self-Antigen-reactive CD8+ T Cells Journal of Immunotherapy ·Kenta Kondo,Fumihiro Fujiki,Hiroko Nakajima,Erika Yatsukawa,Soyoko Morimoto,Naoya Tatsumi,Sumiyuki Nishida,Jun Nakata,Yoshitaka Oka,Akihiro Tsuboi,Naoki Hosen,Yusuke Oji,Haruo Sugiyama	2016	2
12	An Immunocompetent Mouse Model for MLL/AF9 Leukemia Reveals the Potential of Spontaneous Cytotoxic T-Cell Response to an Antigen Expressed in Leukemia Cells PLoS ONE ·Kana Hasegawa,Satomi Tanaka,Fumihiro Fujiki,Soyoko Morimoto,Hiroko Nakajima,Naoya Tatsumi,Jun Nakata,S Takashima,Sumiyuki Nishida,Akihiro Tsuboi,Yoshitaka Oka,Yusuke Oji,Atsushi Kumanogoh,Haruo Sugiyama,Naoki Hosen	2015	13
13	Identification of a Novel C-Terminal Truncated WT1 Isoform with Antagonistic Effects against Major WT1 Isoforms PLoS ONE ·Naoya Tatsumi,Nozomi Hojo,Hiroyuki Sakamoto,R Inaba,Nahoko Moriguchi,Keiko Matsuno,Mari Fukuda,Akihide Matsumura,Seiji Hayashi,Soyoko Morimoto,Jun Nakata,Fumihiro Fujiki,Sumiyuki Nishida,Hiroko Nakajima,Akihiro Tsuboi,Yoshitaka Oka,Naoki Hosen,Haruo Sugiyama,Yusuke Oji	2015	9
14	Establishment of HLA-DR4 Transgenic Mice for the Identification of CD4+ T Cell Epitopes of Tumor-Associated Antigens PLoS ONE ·Junji Yatsuda,Atsushi Irie,Kumiko Harada,Yayoi Michibata,Hirotake Tsukamoto,Satoru Senju,Yusuke Tomita,Akira Yuno,Masatoshi Hirayama,Mohammad Sayem,Naoki Takeda,Isao Shibuya,Shinji Sogo,Fumihiro Fujiki,Haruo Sugiyama,Masatoshi Eto,Yasuharu Nishimura	2013	6
15	In vivo eradication of MLL/ENL leukemia cells by NK cells in the absence of adaptive immunity Leukemia ·Jun Nakata,K Nakano,Atsushi Okumura,Y Mizutani,Hidenori Kinoshita,Miki Iwai,Kana Hasegawa,Soyoko Morimoto,Fumihiro Fujiki,N Tatsumi,Hiroko Nakajima,Yoshiki Nakae,Sumiyuki Nishida,Akihiro Tsuboi,Yusuke Oji,Yoshitaka Oka,Haruo Sugiyama,Atsushi Kumanogoh,Naoki Hosen	2013	8
16	Functional human Th17 clones with WT1-specific helper activity Cancer Immunology Immunotherapy ·Sho Tachino,Fumihiro Fujiki,Yoshitaka Oka,Akihiro Tsuboi,Soyoko Morimoto,Yu‐Hung Lin,Taichi Tamanaka,Kenta Kondo,Hiroko Nakajima,Sumiyuki Nishida,Naoki Hosen,Yusuke Oji,Atsushi Kumanogoh,Haruo Sugiyama	2012	1
17	WT1 Peptide Vaccine as a Paradigm for “Cancer Antigen-Derived Peptide”-Based Immunotherapy for Malignancies: Successful Induction of Anti-Cancer Effect by Vaccination with a Single Kind of WT1 Peptide Anti-Cancer Agents in Medicinal Chemistry ·Yoshitaka Oka,Akihiro Tsuboi,Fumihiro Fujiki,Zheyu Li,Hiroko Nakajima,Naoki Hosen,Toshiaki Shirakata,Sumiyuki Nishida,Yusuke Oji,Ichiro Kawase,Haruo Sugiyama	2009	17
18	Biased usage of BV gene families of T‐cell receptors of WT1 (Wilms’ tumor gene)‐specific CD8⁺ T cells in patients with myeloid malignancies Cancer Science ·Yukie Tanaka‐Harada,Manabu Kawakami,Yoshitaka Oka,Akihiro Tsuboi,Takamasa Katagiri,Elisseeva Olga,Sumiyuki Nishida,Toshiaki Shirakata,Naoki Hosen,Fumihiro Fujiki,Ayako Murao,Hiroko Nakajima,Yusuke Oji,Yoshinobu Kanda,Ichiro Kawase,Haruo Sugiyama	2009	14
19	A WT1 protein‐derived, naturally processed 16‐mer peptide, WT1₃₃₂, is a promiscuous helper peptide for induction of WT1‐specific Th1‐type CD4⁺ T cells Microbiology and Immunology ·Fumihiro Fujiki,Yoshitaka Oka,Mai Kawakatsu,Akihiro Tsuboi,Hiroko Nakajima,Olga A. Elisseeva,Yukie Harada,Zheyu Li,N Tatsumi,Eriko Kamino,Toshiaki Shirakata,Sumiyuki Nishida,Yuki Taniguchi,Ichiro Kawase,Yusuke Oji,Haruo Sugiyama	2008	15
20	WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone Cancer Immunology Immunotherapy ·Hiroko Nakajima,Kotomi Kawasaki,Yoshitaka Oka,Akihiro Tsuboi,Manabu Kawakami,Kazuhiro Ikegame,Yoshihiko Hoshida,Fumihiro Fujiki,Akiko Nakano,Tomoki Masuda,Fei Wu,Yuki Taniguchi,Satoshi Yoshihara,Olga A. Elisseeva,Yusuke Oji,Hiroyasu Ogawa,Ichiro Azuma,Ichiro Kawase,Katsuyuki Aozasa,Haruo Sugiyama	2004	40

About Fumihiro Fujiki

Fumihiro Fujiki is a scholar working on Immunology, Oncology and Molecular Biology, having authored 42 papers that have together received 580 indexed citations. Recurring topics across this work include Renal and related cancers (24 papers), CAR-T cell therapy research (22 papers), Immunotherapy and Immune Responses (20 papers), Epigenetics and DNA Methylation (5 papers), Immune Cell Function and Interaction (5 papers), Cancer Immunotherapy and Biomarkers (5 papers), T-cell and B-cell Immunology (4 papers) and RNA Interference and Gene Delivery (3 papers). The work is most often cited by research in Immunology (292 citations), Oncology (281 citations) and Molecular Biology (320 citations). Fumihiro Fujiki has collaborated with scholars based in Japan, Australia and United States. Frequent co-authors include Haruo Sugiyama, Akihiro Tsuboi, Hiroko Nakajima, Yusuke Oji, Yoshitaka Oka, Naoki Hosen, Sumiyuki Nishida, Soyoko Morimoto, Ichiro Kawase and Jun Nakata. Their work appears in journals such as Blood, PLoS ONE and Neurology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact